Novo’s Wegovy significantly reduces BMI in children aged six to 12
Novo’s subcutaneous Wegovy (semaglutide) has reduced body mass index (BMI) by at least 10% in 80% of children with obesity…
Novo’s subcutaneous Wegovy (semaglutide) has reduced body mass index (BMI) by at least 10% in 80% of children with obesity…